Home › NDC Lookup › RxCUI directory › RxCUI 402244

Bortezomib 3.5 MG Injection [Velcade] — RxCUI 402244

Name: Bortezomib 3.5 MG Injection [Velcade] (RxCUI 402244)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 402244 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI402244

Official nameBortezomib 3.5 MG Injection [Velcade]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asVelcade 3.5 MG Injection

FDA products mapped1

Package NDCs mapped1

Reported Medicaid activity (SDUD)3,052 prescriptions · 25 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bortezomib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It treats adults with multiple myeloma and mantle cell lymphoma. These are both cancers affecting blood-forming cells. Your oncology team decides how it fits into your plan.
A healthcare professional gives it as an injection, into a vein or under the skin depending on the product. Your team sets the dose and schedule for you. You do not take it at home...
Nausea, diarrhea, constipation, tiredness, low blood counts and numbness or tingling are common. Tell your team about them, since medicines can often help. Do not wait if the nerve...
Call for fainting or severe dizziness, new shortness of breath or swelling, seizures, confusion, vision changes, unusual bleeding, or severe vomiting or diarrhea. These can signal...

📖 Read our full Bortezomib guide →

🕸️ Concept Web — How Bortezomib 3.5 MG Injection [Velcade] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Bortezomib 3.5 MG Injection [Velcade] RxCUI 402244 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Bortezomib 358258 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Velcade 356733 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Bortezomib Injection 1804994 SCDF
- Bortezomib Injectable Product 1163075 SCDG
- Bortezomib Injection [Velcade] 1804997 SBDF
- Velcade Injectable Product 1187756 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Bortezomib 3.5 MG Injection 402243 SCD
- Bortezomib 3.5 MG 1804993 SCDC
- Bortezomib 3.5 MG [Velcade] 1804996 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Bortezomib 3.5 MG Injection SCD · 402243
Bortezomib 3.5 MG SCDC · 1804993
Bortezomib Injection SCDF · 1804994
Bortezomib Injectable Product SCDG · 1163075

Brand-Name Concepts

Bortezomib 3.5 MG [Velcade] SBDC · 1804996
Bortezomib Injection [Velcade] SBDF · 1804997
Velcade Injectable Product SBDG · 1187756
Velcade BN · 356733

📦 FDA Products & Package NDCs

1 product · 1 package NDC

1 package NDC map to RxCUI 402244 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
63020-0049-01	1 VIAL in 1 CARTON (63020-049-01) / 1 INJECTION, POWDER, LY...	VELCADE	Takeda Pharmaceuticals America, Inc.	2003-05-13

Observed labelers: Takeda Pharmaceuticals America, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J9041	Injection, bortezomib, 0.1mg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.